BACKGROUND: With products and services being offered round the clock, work timings are no longer restricted from 9 to 5. In fact, there has been an increased demand for workforce to work night shifts which in turn disrupts the circadian rhythm. This causes irritability, mood changes, decrease efficiency, and may eventually catchup with serious disorders. These are referred to as shift work disorders which have been on the rise for past few years.

OBJECTIVES: This study explores the impact of Armodafinil and Modafinil on Metabolic diseases associated with shift work disorder.

METHODS: This retrospective and observational study included patients diagnosed with shift work disorder between 1st March 2017 to 31st Dec 2020 with ICD-10-CM diagnosis recorded in the Optum’s de-identified Market Clarity Database. Metabolic ICD-10 diagnosis codes occurring during study period were identified, grouped, and evaluated during follow-up period. Patients were divided into two cohorts, those who were on Armodafinil and Modafinil and second cohort who were not on any drug for shift work disorder. The year-on-year cost was observed in these cohorts for metabolic disorders. Further, we will carry out propensity score matching between these two groups.

RESULTS: Among 3,102 patients diagnosed with SWD, we observed a year-on-year increase in cost for metabolic diseases of 10% ($12,083 Vs $10,914), 32% ($11,101 Vs $8,402), and 75% ($12,218 Vs $6,991) for 2018, 2019, and 2020 respectively for patients who were not vs those who were on these drugs . The major cost drivers were diabetes mellitus, hypertension, and dyslipidemia. Wilcoxon’s statistical test was found to be significant for all the years.

CONCLUSIONS: Higher utilization for metabolic disease was observed for patients who were not on these drugs. This implies that better control of metabolic diseases was obtained with patients on these 2 drugs or fewer complications of these lifestyle disorders.